scorecardresearch
Saturday, Oct 01, 2022

Roche launches approved treatment for SMA patients Evrysdi

Evrysdi was first approved by the US FDA in August 2020. It is today available in India within 11 months of the US approval.

RocheTo ensure every patient gets access to this disease modifying therapy, Roche will announce its patient support program for Evrysdi. (Reuters)

Roche on Thursday announced the launch of Evrysdi (risdiplam), an approved treatment in India for spinal muscular atrophy (SMA) patients.

Evrysdi was first approved by the US FDA in August 2020. It is today available in India within 11 months of the US approval. Since its launch, over 4,000 SMA patients across 50-plus countries have benefitted from Evrysdi, an official statement issued on Thursday, has said.

SMA is a severe, progressive rare neuromuscular disease that can be fatal. It affects approximately one in 10,000 live births globally and one in 7,744 live births in India and is the leading genetic cause of infant mortality.

It is caused by a mutation of the survival motor neuron 1 (SMN1) gene, which leads to a deficiency of SMN protein. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost.

Subscriber Only Stories
Useless meetings waste time and $100 million a year for big companiesPremium
Jasprit Bumrah has Sushil Kumar like intimidating aura, without him India...Premium
To better track PLI claims, Govt floats digital platforms for data sharingPremium
India-US ties: Depth & nuancePremium

Evrysdi is administered daily at home orally and is designed to treat SMA by increasing production of the survival motor neuron (SMN) protein. It is approved for the treatment of SMA in adults and children two months of age and older.

– Stay updated with the latest Pune news. Follow Express Pune on Twitter here and on Facebook here. You can also join our Express Pune Telegram channel here.

V Simpson Emmanuel, CEO and managing director, Roche Pharma India said, “Today heralds a new journey of hope as we are all coming together to add color into the lives of SMA patients in India with the launch of Evrysdi.”

Patient support program (PSP) to drive access

Advertisement

To ensure every patient gets access to this disease modifying therapy, Roche will announce its patient support program (PSP) for Evrysdi. Through this programme, in the first two years of treatment, Roche will provide three bottles free for every two bottles bought by the patient. From the third year onwards, Roche will provide two bottles free for every one bottle bought by the patient. Patients and caregivers can call 1800-202-4755 for information on the PSP program.

First published on: 29-07-2021 at 08:22:39 pm
Next Story

NTA JEE Main 2021: Provisional answer key released, objection window open till July 31

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement